21 results about "Igm antibody" patented technology

The invention relates to the technical fields of gene engineering, antibody engineering and immunodiagnosis. The invention provides a recombinant humanized anti-Cpn IgM monoclonal antibody. The monoclonal antibody comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprises three complementary determining regions CDR1, CDR2 and CDR3, and the amino acid sequences of the three complementary determining regions are respectively shown as SEQ ID NO.3, SEQ ID NO.4 and SEQ ID NO.5; the heavy chain variable region comprises three complementary determining regions CDR1, CDR2 and CDR3, and the amino acid sequences of the three complementary determining regions are shown as SEQ ID NO.6, SEQ ID NO.7 and SEQ ID NO.8 respectively. The invention also provides a method for preparing the monoclonal antibody. The recombinant humanized anti-Cpn IgM monoclonal antibody provided by the invention is expressed in mammalian cells by utilizing a gene recombination technology, has the characteristics of high purity, small batch difference and the like, and can be applied to a Cpn IgM antibody detection kit as a quality control product; as a quality control product, the recombinant humanized anti-Cpn IgM monoclonal antibody has the advantages of high sensitivity, high safety, inter-batch stability and the like.

The application provides a combined detection test strip for dengue virus, Zika virus antigen and antibody and a preparation method thereof; the combined detection test strip of the application adopts a multi-site recombinant antigen marking or multi-site recombinant antibody coating form for the combined detection test strip for dengue virus NS1 antigen and dengue virus IgG / IgM antibody, thereby improving the sensitivity of the reagent; the application also overcomes the problems of poor specificity and release residue of the latex microspheres by optimizing a blocking solution; color latex microspheres are used as the markers, the target is more intuitively detected according to the color of the lines, clinical result interpretation is facilitated, the accuracy of dengue virus infection and Zika virus infection is improved, dengue virus NS1, Zika virus NS1 antigen, dengue virus IgG / IgM antibody detection and Zika virus IgG / IgM antibody can be simultaneously detected; moreover, the application is convenient to carry and easy to operate, is convenient for on-site instant detection and can be used for large-scale preliminary screening.

The present application relates to the field of biotechnology, and more particularly to a SNP marker related to the level of anti-streptococcus agalactiae IgM antibody of tilapia and application thereof. The present application screens out QTLs, functional genes and key signal pathways significantly related to the level of anti-streptococcus agalactiae IgM antibody of tilapia by RNA-Seq and BSA-Seq technologies, and further identifies two SNP markers closely related to the level of anti-streptococcus agalactiae IgM antibody of tilapia, thereby providing important genetic targets and tools for molecular marker-assisted breeding of anti-streptococcus agalactiae of tilapia.

The present invention relates to an IgM antibody formulation and uses thereof. In particular, the IgM antibody formulation comprises an IgM antibody, which is an IgM antibody formed by a nanobody fusion protein and a J chain, the nanobody fusion protein is a fusion protein comprising a nanobody and an Fc fragment, which are optionally linked by a linker, wherein the formulation further comprises a buffer selected from a citrate buffer system, optionally the formulation further comprises one or more of a stabilizer, an osmotic pressure regulator and a surfactant.

An immunological analysis mode of a novel total antibody assay and a kit for detecting antibodies of infectious diseases in human blood samples according to the mode, the kit comprising: a first reagent containing at least one antigen coated on a solid support and an anti-human IgM antibody coated on a solid support; and a second reagent containing at least one labeled antigen and a labeled anti-human IgG antibody; wherein at least one antigen of the at least one antigen coated on the solid support and at least one antigen of the at least one labeled antigen can bind to the same IgG antibody or the same IgM antibody in the sample. The kit can overcome the disadvantages caused by the detection principle while retaining the advantages of each detection principle. In addition, a method for detecting antibodies produced after pathogen infection in a sample is provided.

The invention discloses a non-human animal integrated with a double-derived VH subclass fusion gene as well as a construction method and application of the non-human animal. The method comprises the following steps: firstly, constructing a gene construct containing human IGHV1-69 and IGHV3-23 fragments, a specific spacer region, a functional element and a rat heavy chain 3'enhancer, and microinjecting the gene construct into a C57BL / 6J fertilized egg with an endogenous heavy chain and a kappa light chain knocked out to obtain a transgenic mouse; through identification, after a mouse endogenous antibody is inactivated, a human gene is stably integrated, a human IgM antibody is expressed and H5N1 HA immunization is carried out, the use frequency of IGHV1-69 is remarkably increased, the mouse produces a high-titer specific antibody, and serum has neutralizing activity. The mouse can generate a target bnAbs aiming at the HA stem and the RBS in parallel, so that the antibody screening efficiency is improved, and an in-vivo screening and evaluation platform for simulating human body fluid response is provided for research and development of influenza antibodies and vaccines.

Provided herein are antibodies, such as IgM antibodies, that bind to human PSGL-1. These antibodies can be used in a variety of diagnostic and therapeutic methods, including, without limitation, treating T-cell mediated inflammatory diseases, cancers, transplantations, and transfusions.

The invention discloses a pathogenic microorganism infection IgM antibody hypersensitivity detection method based on PEG mixed sensitization-three-stage gradient washing-ALP double activation collaborative optimization and a kit. The method is characterized in that PEG 6000 and PEG 20000 are matched according to a ratio of 4: 1 to synergistically enhance sensitivity and strengthen antigen-IgM binding; three-stage gradient washing decoupling background reduction and enzyme activity keeping contradiction; an ALP double-activation system (Mg < 2 + > / Zn < 2 + > + 5-(myristyl amino) fluorescein + Gemini) improves the enzyme activity to be greater than or equal to 320U / mg. The kit contains six reagents such as PEG-biotin labeled antigens, the detection limit is smaller than or equal to 0.5 pg / mL (1000 times higher than that of a traditional reagent), the background is smaller than or equal to 350RLU, the cross reaction rate is smaller than or equal to 0.2%, the detection rate within 3 days of disease attack is larger than or equal to 90%, and the activity attenuation is smaller than or equal to 8% after the kit is stored at 4 DEG C for 12 months. The replacement of specific antigens can be expanded to detection of other pathogens / tumor markers.

The application discloses an anti-IgM antibody and application thereof, and relates to the field of antibodies.The anti-human IgM antibody provided by the application comprises a heavy chain complementarity determining region and a light chain complementarity determining region, has a good blocking and immune interference eliminating effect, and provides an important blocking agent raw material.

The invention discloses a riemerella anatipestifer glucosamine oligosaccharide protein conjugate as well as a preparation method and application thereof, the glucosamine oligosaccharide protein conjugate is formed by connecting glucosamine oligosaccharide and carrier protein through a linking group, and the structural general formula of the glucosamine oligosaccharide protein conjugate is as shown in formula (III). The glucosamine oligoglycoprotein conjugate with a clear structure is prepared by utilizing a chemical synthesis method. An enzyme-linked immunosorbent assay experiment result shows that serum of a positive immune mouse and glucosamine oligosaccharides with different chain lengths have different recognition effects, and the glucosamine oligoglycoprotein conjugate can excite an antigen-specific IgG antibody with very high titer and an IgM antibody with high titer, induce a strong T-cell dependent protective immunoreaction, and can be used for preparing the immunosorbent assay kit. After immunization, serum can be obviously combined with inactivated riemerella anatipestifer. Therefore, the glucosamine oligosaccharide protein conjugate provided by the invention has relatively high application value in preparation of vaccines for resisting riemerella anatipestifer infection and drug development. In addition, the preparation steps are simple, and the yield is high.

This invention proposes an immunomicrofluidic chip for the joint detection of IgM and IgG antibodies against the same pathogen and its application. The chip includes a substrate and a cover plate pressed onto the substrate. The substrate and cover plate together form a microchannel. From left to right, the microchannel has a labeled area and a detection area. The detection area includes an IgG detection area and an IgM detection area. The upper surface of the substrate, corresponding to the labeled area, is coated with labeled anti-human IgG antibody, and the upper surface of the substrate, corresponding to the IgG detection area, is coated with recombinant pathogen antigen. The lower surface of the cover plate, corresponding to the labeled area, is coated with labeled antigen, and the lower surface of the cover plate, corresponding to the IgM detection area, is coated with anti-human IgM antibody. By integrating the IgM antibody capture detection area and the IgG antibody indirect detection area into separate fluid layers of the chip, simultaneous but non-interfering detection of IgM and IgG antibodies in the same channel can be achieved after a single sample injection.

This application relates to a method, kit, and application for detecting IgM antibodies. The method includes the following steps: mixing a hydrolysis reagent containing a proteolytic enzyme and an immunoassay reagent capable of specifically binding to the target IgM antibody in the test sample with the test sample to obtain a test reaction solution; detecting the signal value of the reaction solution; wherein the proteolytic enzyme can destroy the structure of interfering proteins in the test sample. The solution provided in this application can reduce or eliminate the interference of matrix effects produced by interfering proteins, thereby improving the detection accuracy of IgM antibodies.

The present disclosure provides a photo-activated chemiluminescence detection kit and method for detecting hepatitis B virus core IgM type antibody. The detection kit comprises: reagent 1, luminescent microspheres coated with hepatitis B core antigen (HBcAg), which can react with singlet oxygen and generate a detectable light signal; reagent 2, anti-IgM antibody labeled with a first partner; and reagent 3, blocking reagent, which can reduce or eliminate interfering antibodies. The detection kit of the present disclosure destroys the structure of interfering antibodies by chemical and / or biological methods, thereby weakening or even eliminating the signal or shielded signal caused by interfering antibodies, which can significantly improve the accuracy of hepatitis B virus core IgM type antibody detection.

A novel immunoassay format design for determining a total antibody, and a kit accordingly provided for detecting antibodies of a pathogen or pathogens of infectious diseases within a human blood sample are provided. The kit includes: a first reagent containing at least one antigen coated on a solid phase support and an anti-human IgM antibody coated on a solid phase support; and a second reagent containing at least one labelled antigen and a labelled anti-human IgG antibody. At least one antigen of the at least one antigen coated on a solid phase support and at least one antigen of the at least one labelled antigen can bind to the same IgG antibody or the same IgM antibody in the sample. In addition, also provided is a new method for detecting an antibody produced after the infection of a pathogen or pathogens in a sample.

The invention provides a preparation method of an ictalurus punctatus IgM antibody based on a prokaryotic expression system, and relates to the field of aquatic animal immunodetection and antibody preparation, and the preparation method comprises the following steps: designing a specific primer based on an ictalurus punctatus IgM protein gene sequence in GenBank, and carrying out antigen determinant truncation; the method comprises the following steps: extracting liver RNA (Ribonucleic Acid) of channel catfish by a Trizol method, reversely transcribing the liver RNA into cDNA (Complementary Deoxyribonucleic Acid), and cloning an IgM The method comprises the following steps: constructing a pET-30a-IgM recombinant expression vector, transforming Escherichia coli Rosetta competent cells, and inducing protein expression; purifying the truncated IgM protein by adopting the steps of ultrasonication, affinity chromatography and dialysis concentration; a New Zealand white rabbit is immunized to prepare antiserum, and the titer is detected through ELISA. According to the method, efficient and low-cost preparation of the IgM protein is realized by utilizing a prokaryotic expression system, the period is only several weeks, high-purity protein of milligram-grade to gram-grade can be obtained, the batch stability is good, related biological safety risks of animal serum are avoided, and a key basis is provided for development of an ictalurus punctatus ELISA (enzyme-linked immunosorbent assay) kit, immunohistochemistry and B lymphocyte research.

This invention proposes a microfluidic chip for the combined detection of hepatitis A / hepatitis E virus IgM antibodies and its application. The chip includes a substrate and a cover plate pressed onto the substrate. The substrate and cover plate enclose a microchannel, which is provided with a labeling area and a detection area. The labeling area includes a first labeling area on the lower surface of the cover plate and a second labeling area on the upper surface of the substrate. The detection area includes an HEV-IgM antibody detection area on the lower surface of the cover plate and a HAV-IgM antibody detection area on the upper surface of the substrate. An IgG antibody capture area is provided on the upper surface of the substrate directly below the sample injection well. The IgG antibody capture area contains magnetic microspheres containing anti-human IgG antibodies. The first labeling area contains labeled HEV antigen, the second labeling area contains labeled anti-human IgM antibody, the HEV-IgM antibody detection area contains anti-human IgM antibody, and the HAV-IgM antibody detection area contains HAV antigen. The capture method and the indirect method are used in parallel to achieve the combined detection of IgM antibodies related to the two viruses.

To provide a method, a reagent and a kit for accurately measuring N-terminal pro-brain natriuretic peptide (NT-proBNP) in a sample with high sensitivity.SOLUTION: In a latex agglutination immunoassay method for NT-proBNP in a sample, N-terminal pro-brain natriuretic peptide (NT-proBNP) in the sample is reacted with latex particles to which an antibody recognizing NT-proBNP or an antibody fragment thereof is bound in an aqueous medium in the presence of a reduced anti-IgM antibody.SELECTED DRAWING: None

The invention relates to the technical field of antibodies, in particular to an anti-chlamydia pneumoniae monoclonal antibody as well as a preparation method and application thereof. The anti-chlamydia pneumoniae monoclonal antibody (CP-IgM antibody) provided by the invention can specifically recognize a chlamydia pneumoniae antigen, is good in stability, and can be used as a raw material of a chlamydia pneumoniae detection reagent quality control product, so that the screening efficiency of the raw material is greatly improved, and the difficulty of batch difference control of the raw material is greatly reduced. The CP-IgM antibody is used as a raw material of the chlamydia pneumoniae detection reagent quality control product, so that the detection sensitivity and accuracy are improved. The recombinant antibody human CP IgM prepared by the invention can be used for a CP IgM detection kit, the monoclonal antibody can be used as a positive quality control product, the titer, the stability and the matrix effect of the monoclonal antibody all meet the use requirements, and a reliable basis is provided for clinical diagnosis and treatment.

The invention relates to the technical field of biological detection, and relates to a CP-IgM antibody, a preparation method and application thereof, a nucleic acid molecule, a carrier, a cell, a quality control product, a kit and a detection method of the CP-IgM antibody. The CP-IgM antibody has CDR-L1 to CDR-L3 of which the amino acid sequences are as shown in SEQ ID NO.2 to SEQ ID NO.4, and CDR-H1 to CDR-H3 of which the amino acid sequences are as shown in SEQ ID NO.6 to SEQ ID NO.8. As a quality control antibody, the CP-IgM can overcome the problems of low signal, too strong matrix effect and the like of the traditional CP-IgM.

The invention discloses an antibody combination, a composite quality control product containing the antibody combination and application of the antibody combination to detection of new bunyavirus NP protein. The antibody combination comprises an IgG antibody and an IgM antibody; the IgG antibody comprises a heavy chain variable region 1 and a light chain variable region 1; the IgM antibody comprises a heavy chain variable region 1 and a light chain variable region 1. The antibody combination can be used for preparing a composite quality control product of a new bunyavirus antibody detection kit, and the problems of potential infection risk, large batch-to-batch difference, difficulty in management of quality control of a plurality of projects, high cost and the like caused by traditional serum sample dilution as quality control are solved.

This disclosure provides an IgM antibody or IgM-like antibody comprising a variant J-chain and / or variant IgM heavy chain constant regions that can confer increased serum half-life upon the antibody.